Researchers have uncovered a distinct neural circuit that regulates appetite and energy expenditure, opening doors to new ...
From cancer biology to proactive health management, customized care is changing patient outcomes, but what are the costs and ...
The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the ...
The market for illicit weight-loss drugs is booming in plain sight. And the U.S. Food and Drug Administration is starting to ...
“Bi-specific ADCs hold significant promise as the next generation of cancer therapies,” mentioned Bertrand Ducrey, CEO of Debiopharm. “We’re excited to confirm this licensing option as it allows us to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback